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Abstract Immunoassays are routinely used as research tools
to measure intracellular cAMP and cGMP concentrations.
Ideally, this application requires antibodies with high sensi-
tivity and specificity. The present work evaluates the cross-
reactivity of commercially available cyclic nucleotide analogs
with two non-radioactive and one radioactive cAMP and
cGMP immunoassay. Most of the tested cyclic nucleotide
analogs showed low degree competition with the antibodies;
however, with Rp-cAMPS, 8-Br-cGMP and 8-pCPT-cGMP , a
strong cross-reactivity with the corresponding cAMP and
cGMP , respectively, immunoassays was observed. The deter-
mined EIA-binding constants enabled the measurement of the
intracellular cyclic nucleotide concentrations and revealed a
time- and lipophilicity-dependent cellmembranepermeability
of the compounds in the range of 10–30% of the extracellular
applied concentration, thus allowing a more accurate predic-
tion of the intracellular analog levels in a given experiment.
Keywords Cyclic nucleotides.Enzyme immunoassay.
Lipophilicity.Cell permeability
Introduction
The second messengers cAMP and cGMP control a multitude
of cellular processes, such as gene transcription, chemotaxis,
proliferation, differentiation and apoptosis. In this regard,
cAMP and cGMP enzyme immunoassays (EIA) and radioac-
tive immunoassays (RIA) are routinely used as research tools
toestimatetheconcentrationofthecyclicnucleotidesinacell.
The cAMP and cGMP immunoassays are based on the
competition of free cyclic nucleotide with linked cAMP or
cGMP tracer. Routinely, the cyclic nucleotide antibodies are
analysed for cross-reactivity with the mono-, di- and
triphosphates of several nucleotides (e.g. ADP , GTP and
CTP); however, nonspecific binding of cyclic nucleotide
derivatives is not determined.
In the last 30 years, a large variety of cyclic nucleotide
analogs (e.g. 8-Br-cAMP , 8-pCPT -cGMP and 8-pCPT-2′-O-
Me-cAMP; Poppe et al. 2008)a sw e l la sp u r i n e - b a s e d
phosphodiesterase inhibitors (IBMX, theophylline) have
been applied to study intracellular cAMP and cGMP path-
ways and to manipulate cyclic nucleotide binding partners
like ion channels (Craven and Zagotta 2006), protein kinases
(Lohmann and Walter 2005), phosphodiesterases (Omori and
Kotera 2007) and exchange proteins directly activated by
cAMP (Epac; Gloerich and Bos 2010) in intact cells. Based
on their purine-riboside structure, these synthetic derivatives
have the potential to interfere with the cAMP- and cGMP-
EIAs to give false positive results. We therefore tested the
most commonly applied cyclic nucleotides for their compe-
tition with the specific cAMP and cGMP antigens in two
frequently used commercial EIAs in vitro and with intact
cells (Horton et al. 1992). In addition, a set of systematically
modified cyclic nucleotide analogs was chosen to map the
epitope interaction of the polyclonal antibodies and to predict
potential cross-reactivities with novel derivatives.
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DOI 10.1007/s00210-011-0662-6Due to their polar ionic structure, cAMP and cGMP are
not able to penetrate intact cellular membranes. Therefore,
cyclic nucleotide analogs with lipophilic substituents are
used in intact cell experiments to mimic the intracellular
effects of cAMP and cGMP . However, the concentrations
needed for a given cell line have to be determined laborious
in dose–response experiments. On the basis of the EIA data
raised in this study, we are now able to measure the
intracellular concentration of extracellularly applied cyclic
nucleotides and to predict the bioavailability of the
derivatives in accordance to their lipophilicity index.
Methods
Cyclic nucleotide analogs
All cyclic nucleotides and derivatives (Supplementary Figs. S1
and S2) were from Biolog Life Science Institute (Bremen,
Germany) and diluted in aqua dest. The PDE inhibitors
3-isobutyl-methyl-xanthine (IBMX), theophylline and erythro-
9-(2-Hydroxy-3 nonyl)-adenine hydrochloride (EHNA) (Sup-
plementary Fig. S3) were obtained from Sigma-Aldrich
(Deisenhofen, Germany) and diluted in DMSO.
Cyclic nucleotide enzyme immunoassay (EIA) and radio
immunoassay (RIA)
For measuring cyclic nucleotide concentrations, the non-
radioactive cAMP- and cGMP-EIA kits from ENZO Life
Sciences (Loerrach, Germany), the cGMP-EIA from Cayman
(IBL International, Hamburg, Germany) and the radioactive
cAMP- and cGMP-RIA kits from IBL (Hamburg, Germany)
were used following the instructions of the manufacturer. If
not stated otherwise, all experiments were performed with the
acetylation protocol to achieve maximum sensitivity. The
yellow-coloured product formed with the EIAs is inversely
proportional to the amount of cyclic nucleotide present in the
sample and was detected at 405 nm by a multiple counter
(Victor
2™ 1420, Wallac/Perkin Elmer, Rodgau, Germany).
Radioactivity (I-125) was detected with a Berthold Counter
LB 2104 (Bad Wildbad, Germany). All experiments were
done three times in duplicate.
Preparation of washed human platelets
All procedures were carried out at room temperature. Blood
was drawn from healthy volunteers, who gave informed
consent and had been medication-free for 10 days, using
venipuncture with a hollow needle into CCD-EGTA-buffer
(20 mM sodium citrate, pH 6.5, 1.5 mM citric acid, 10 mM
glucose, 4 mM EGTA, final concentration). Platelet-rich
plasma was prepared by 20-min centrifugation at 300×g.
After 5 min rest, platelets were pelleted by 10-min
centrifugation at 380×g, washed once in resupension buffer
(10 mM Hepes, pH 7.4, 145 mM NaCl, 5 mM KCl, 1 mM
MgCl2, 10 mM glucose) and resuspended at a final
concentration of 3×10
8 platelets/ml (washed platelets).
Platelet count was determined using a Technicon H.3 RTC
blood cell counter (Bayer, Frankfurt, Germany).
Cell culture
Chinese hamster ovarian cells (CHO) were grown on 75-cm
2
culture flasks in 15 ml of Dulbecco's modified Eagle's
medium (Invitrogen, Karlsruhe, Germany), supplemented
with10% foetalbovineserum and 1%penicillin/streptomycin
solution (Sigma-Aldrich, Deisenhofen, Germany). Cells were
maintained at 37°C in a humidified atmosphere of 5% CO2
and 95% air.
Cell membrane permeability
Cell membrane permeability of cyclic nucleotides was
determined by incubating300μlwashedplateletswithvarious
concentrationsofcyclicnucleotidesat37°Cforthe time points
indicated (normally 20 min). After centrifugation (1 min,
720×g) and removal of the analog containing supernatant,
cells were resuspended in 300 μl hypertonic buffer (10 mM
Hepes, pH 8.1, 10 mM KCl, 1.5 mM EDTA, 200 mM
sucrose, 1 mM IBMX) and left on ice for 30 min. For CHO
cell permeability measurements, cells were incubated with
various analog concentrations in serum-free medium for the
time points indicated (normally 20 min), washed with PBS,
covered with 300 μl hypotonic buffer, left on ice for 30 min,
scraped off and transferred into a reaction tube.
Further cell disruption was done for both cell types in a
freeze/thaw cycle with liquid nitrogen followed by needle
disruption. After centrifugation (10 min, 20.800×g, 4°C), the
cyclic nucleotide containing supernatant was lyophilized and
then used in the EIA.
SDS-PAGE and western blot
Ten microgrammes of the protein extracts were separated
by 9% SDS-PAGE under reducing conditions and trans-
ferred onto nitrocellulose membranes by the wet method.
After blocking with 3% non-fat dry milk in 10 mM Tris
buffer, pH 7.5, 150 mM NaCl, and 0.1% (w/v) Tween 20,
the membrane was incubated with the 16C2 antibody raised
against pV ASP Ser-239 (PKG site) or 5C6 antibody raised
against pV ASP Ser-157 (PKA site; both 1:10,000, Nano-
tools, Freiburg, Germany) followed by incubation with
horseradish peroxidase-coupled goat anti-mouse IgG (Bio-
rad, Munich, Germany), diluted 1:5,000 and visualized by
ECL (GE-Healthcare, Freiburg, Germany).
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The binding constants were calculated according to the Hill
equation:
y ¼ ymax  
xslope
xslope þ EC50
slope

þ ymin
where x is the concentration of cyclic nucleotide, y the
percentage of binding (percent B/B0)a n dE C 50 the
concentration of the standard or the analogs entailing 50%
binding. Binding curves were determined for each deriva-
tive with at least six different concentrations in duplicates
and with platelets from three different donors. EC50 values
were calculated using GraphPad Prism 4 software (Graph-
Pad, San Diego, CA, USA). Binding constants of the cyclic
nucleotide analogs were calculated by dividing the EC50
derivative concentrations by the EC50 values of the cAMP
or cGMP standards. To define the percentage of cyclic
nucleotide analog permeability, the calculated intracellular
concentration was divided by the used extracellular con-
centration and then multiplied by the binding constant
(Supplementary Tables 1 and 2).
For calculating intracellular analog concentrations, cell
volumes of 5.2 fl for platelets and 1.5 pl for CHO cells were
taken as a basis (Eigenthaler et al. 1992;L ue ta l .2003).
Results and discussion
Epitope mapping
A series of systematically modified cAMP and cGMP
analogs (Supplementary Figs. S1 and S2) was used to map
the essential molecular interactions between cAMP or
cGMP , respectively, and the polyclonal antibodies supplied
with the ENZO enzyme immunoassay (Supplementary
Tables 1 and 2).
In solution, cAMP preferentially arranges in the anti-
conformation, while analogs with bulky substituents at the 8-
position (8-Br-cAMP) stabilize the molecule in the syn-
conformation (Lassota et al. 1984). The reduced affinity of
8-Br-cAMP to the cAMP-EIA paratope indicates binding of
the nucleotide to the cAMP antibody in the anti-conformation.
Due to formation of an intra-molecular H-bond between
the phosphate ring and the 2-amino group, cGMP is
stabilized and bound to the cGMP-EIA antibody in the
syn-position. 8-Br-cGMP and 8-pCPT-cGMP further stabi-
lize this conformation and thus exhibit stronger binding
constants than cGMP .
Discrimination of cAMP and cGMP by substituents in 1- or
6-positionisless pronouncedasexpected.Apparently,cGMPis
recognized by the hydrogen bond accepting oxygen at the 6-
position (6-SH-cGMP and 2-NH2-cPuMP show considerably
reduced binding), while the hydrogen-bond donor NH2-group
at position 6 in the cAMP molecule is not involved in
antibody binding (only 20% reduced binding of cPuMP).
The Rp- and Sp-phosphorothioates (Rp/Sp-cGMPS; Sp-
cAMPS) with an exocyclic sulphur, a substitution leading to
increased size, polarisability and altered distribution of the
negative charge (Frey and Sammons 1985), show a less
pronounced binding than cGMP and cAMP , demonstrating the
importance of the ionic interaction between antibody and
cyclic phosphate moiety. Surprisingly, Rp-cAMPS (Supple-
mentary Fig. S1, compound 7) does not show reduced
binding (compare cAMP with Rp-cAMPS and 8-Br-cAMP
with Rp-8-Br-cAMPS, respectively). It is concluded that the
equatorial oxygen in cAMP and the corresponding sulphur in
Rp-cAMPS/Rp-8-Br-cAMPS are recognized by the cAMP-
EIAwith similar, presumably weak and non-essential molec-
ular interactions. In contrast, the axial sulphur in Sp-cAMPS
obviously generates significant steric or electrostatic repulsion
in a distinct region of the binding pocket. The decreased
affinities observed for 2′-dcAMP and 2′-dcGMP are condi-
tional upon the method. The 2′-deoxy modification blocks the
acetylation desired at this position and therefore leads to
reduced assay sensitivity. Without acetylation, 2′-dcGMP
shows a moderately increased binding affinity (2.2-fold)
compared to cGMP in the non-acetylated cGMP-EIA, while
the relative binding values for 8-Br-cGMP and 8-Br-PET-
cGMP were not affected (Table 1). A similar observation of
reduced binding difference was made for cAMP and 2′-
Analog Absolute binding
EC50 [M] non-acetylated
Relative binding
EC50cGMP/EC50Analog
Relative binding
EC50cAMP/EC50Analog
cGMP 1.17×10
−08 1.00
2′-dcGMP (17) 5.28×10
−09 2.21
8-Br-cGMP (15) 1.83×10
−09 6.40
8-Br-PET-cGMP (22) 1.36×10
−07 0.08
cAMP 4.2×10
−09 1.00
2′-dcAMP (6) 1.9×10
−08 0.22
Table 1 Binding specificities of
non-acetylated cGMP and
cAMP analogs measured with
the cGMP- and cAMP-EIA,
respectively, from ENZO
The EC50 values represent
means (SEM) of three experi-
ments in duplicate
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all, acetylation enhances the sensitivity of the EIAs but does
not affect the relative binding values obtained without
acetylation.
Cross-reactivities
The chemical structures of the cyclic nucleotide derivatives
tested are shown in Supplementary Fig. S1 (cAMP analogs),
Table 2 Relative binding specificities of cyclic nucleotide analogs measured with various cGMP and cAMP immunoassays as described under
“Methods” section
Analog Specificity ENZO
cAMP-EIA
Specificity IBL
cAMP-RIA
Specificity ENZO
cGMP-EIA
Specificity IBL
cGMP-RIA
Specificity Cayman
cGMP-EIA
cAMP 1.00 1.00
cGMP 1.00 1.00 1.00
2′-dcGMP 0.052
Rp-cGMPS 0.0027 0.10
2′-dcAMP 0.034
8-Br-cGMP (15) 4.90 0.20 0.005
Rp-cAMPS (7) 0.68 0.67
8-Br-cAMP (4) 0.004 0.026
Rp-8-Br-cAMPS (12) 0.003
6-MB-cAMP (1) 0.004 0.012
6-Bnz-cAMP (2) 0.006 0.009
8-pCPT-cGMP (16) 2.40 0.30 0.0008
8-pCPT-cAMP (5) 0.0005
8-Br-PET-cGMP (22) 0.10 0.015 0.016
Rp-8-Br-PET-cGMPS (23) 0.002 0.011
8-pCPT-2′-OMe-cAMP (10) 0.0003 0.0066 0.0002 <10
−4
Sp-5,6-DCl-cBIMPS (11) <10
−4 0.005
IBMX (26) <10
−5 <10
−4 <10
−6 <10
−6 <10
−5
The analogs are ordered according to their lipophilicity (see Table 4). Specificity is expressed as EC50cGMP or cAMP/EC50Analog. The absolute EC50
binding constants for acetylated cAMP in [M] are 7.62×10
−10 (ENZO) and 5.8×10
−9 (IBL); for acetylated cGMP in [M]: 2.27×10
−10 (ENZO),
1.8×10
−9 (IBL) and 3.9×10
−10 (Cayman)
Table 3 Cell membrane permeability and activation constants for selected cyclic nucleotide analogs
Analog cNMP conc. inside
platelets (% of external)
cNMP conc. inside
CHO cells (% of external)
Lipophilicity
a
log Kw
Activation
b PKG
Iβ Ka (μM)
Activation
b PKA
II Ka (μM)
cGMP 0.77 0.9
2′-dcGMP (17) 0.5±0.1 0.3±0.5 0.66 21
8-Br-cGMP (15) 12.1±3.5 13.5±11.5 1.17 1.0
8-pCPT-cGMP (16) 19.6±4.7 n/d 2.52 0.9
8-Br-PET-cGMP (22) 30.9±5.7 24.1±9.7 2.83 0.009
cAMP 1.09 0.08
2′-dcAMP (6) 0.2±0.3 0.1±0.2 0.97 n/d
8-Br-cAMP (4) n/d n/d 1.35 0.09
Sp-5,6-DCl-cBIMPS (11) n/d n/d 2.99 0.12
All experiments were performed three times
n/d not determined
aKrass et al. (1997)
bPoppe et al. (2008)
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Fig. S3 (PDE inhibitors). Dose–response curves were
prepared using different concentrations of cyclic nucleotide
analogs (Supplementary Fig. S4).
In the cAMP-EIA, significant cross-reactivity was ob-
served only with cPuMP and the PKA inhibitor Rp-cAMPS
(Supplementary Table 1). A similar interference was also
mentioned by Grazul-Bilka and colleagues. In their study,
Rp-cAMPS and dibutyryl-cAMP , both were recognized by a
cAMP-RIA from DuPont/NEN (Grazul-Bilska et al. 1996).
Due to its low lipophilicity, Rp-cAMPS is not frequently
used for in vivo experiments; however, studies with Rp-
cAMPS in combination with cAMP determination are
reported (Fan et al. 2009).
The most prominent competitors in the ENZO cGMP-EIA
with superior binding constants compared to cGMP are 8-Br-
cGMP and 8-pCPT-cGMP (Table 2 and Supplementary
Table 2), two PKG activators frequently used in intact cells.
The PKG activator 8-Br-PET-cGMP still exhibits 10% of the
cGMP affinity to the antibody used in the assay. Occasion-
ally, these compounds are used to investigate effects of PKG
on PDE activity. In some studies, the measured intracellular
cGMP levels are far too high and imply cross-reactivity of
the applied cGMP analogs with the used immunoassays
(Y oshioka et al. 2000; Bosgraaf et al. 2002). With regard to
our data, the measurement of cGMP concentrations in the
presence of 8-Br-cGMP or 8-pCPT -cGMP should be avoided
with the ENZO cGMP-EIA, while the use of 8-Br-PET -
cGMP is recommended. Conversely, this kit can be used to
determine cellular uptake or secretion of 8-Br-cGMP and 8-
pCPT-cGMP .
In consequence, we tested some of the interfering deriva-
tives with a second cGMP-EIA (Cayman Chemical Company)
and two radioactive immunoassays (IBL International). While
the Cayman EIA assayis lesssensitive to cGMP (1.0 pmol/ml)
than the ENZO cGMP-EIA (0.01 pmol/ml), the specificity
concerning cGMP analogs is superior: cGMP 1.00, 8-Br-
PET -cGMP 0.16, 8-Br-cGMP 0.05 and 8-pCPT-cGMP 0.0008
(Table2). The Cayman assay is therefore advantageous when
measuring cGMP in the presence of 8-Br-cGMP and 8-
pCPT-cGMP .
The cAMP- and cGMP-RIA from IBL exhibit lower
cross-reactivities with the selected cNMP analogs than the
ENZO assays; however, binding constants in the range of
20% for 8-Br-cGMP and 30% for 8-pCPT-cGMP with the
cGMP-RIA as well as 66% for Rp-cAMPS with the cAMP-
RIA are still far too high for measuring cAMP and cGMP
concentrations in intact cells in the presence of theses
cNMP analogs (Table 2).
The two nonspecific PDE inhibitors theophylline and
IBMX as well as the PDE 2 inhibitor EHNA (Supplementary
Fig.S3) do not interfere with any of the tested immunoassays
(Table 2 and Supplementary Tables 1 and 2) at all. Therefore,
measurement of cGMP and/or cAMP is feasible even if these
inhibitorsare usedinthe millimolarrange sometimesrequired
for experiments in intact cells for efficient PDE inhibition.
Also, the Epac activator 8-pCPT-2′-O-Me-cAMP does not
cross-react with either immunoassay; however, inhibition of
certain phosphodiesterases by 8-pCPT -2′-O-Me-cAMP can
indirectlyaffectendogenouscGMPlevels(Poppeetal. 2008).
Cell membrane permeability
Passive diffusion is the major route for cell permeation of
most drugs and predominantly governed by lipophilicity,
polarity, charge and size of the respective molecule. We
have selected cyclic nucleotide analogs covering a wide
range in lipophilicity (log Kw; Krass et al. 1997; http://
www.biolog.de/technical-info/lipophilicity-data/) and deter-
mined their cell membrane permeability with human
platelets and CHO cells (Table 3).
For cyclic nucleotides with a molecular weight of about
350±150, membrane diffusion without restriction is assumed
Table 4 Lipophilicity and cell membrane permeability of cyclic
nucleotide analogs
Analog    Lipophilicity
a
log Kw
Permeability
1-NO-cAMP (9) 0.65
2`-dcGMP (17) 0.66 0 %
cGMP 0.77
7-CH-cGMP (14) 0.81
Rp-cGMPS (18) 0.89
2-NH2-cPuMP (21) 0.95
2`-dcAMP (6) 0.97 0 %
Sp-cGMPS (19) 1.02
cPUMP (20) 1.03
cAMP 1.09
8-Br-cGMP (15) 1.17 12.1 %
7-CH-cAMP (3) 1.21
Rp-cAMPS (7) 1.21 12.2 %
6-SH-cGMP (13) 1.32
Sp-cAMPS (8) 1.32
8-Br-cAMP (4) 1.35 8.0 %
b
Rp-8-Br-cAMPS (12) 1.47
6-MB-cAMP (1) 1.64
6-Bnz-cAMP (2) 1.90
8-pCPT-cGMP (16) 2.52 19.6 %
8-pCPT-cAMP (5) 2.65 22.0 %
b
8-Br-PET-cGMP (22) 2.83 30.9 %
Rp-8-Br-PET-cGMPS (23) 2.83
8-pCPT-2`-OMe-cAMP (10) 2.94
Sp-5,6-DCl-cBIMPS (11) 2.99
Lipophilicity is expressed as partition coefficient (log Kw) of the
analog between methanol and water. Permeability represents percent-
age of intracellular measured cyclic nucleotide content as a function of
external applied concentration
aKrass et al. (1997)
bBartsch et al. (2003)
Naunyn-Schmiedeberg's Arch Pharmacol (2011) 384:169–176 173(Camenisch et al. 1998). In general, the intracellular cyclic
nucleotide concentrations measured confirm the expected
correlation of lipophilicity and permeability (Table 4). Com-
pounds with low lipophilicity (log Kw<1) are too hydrophilic
for any diffusion into the cell (2′-dcGMP , 2′-dcAMP). At a
log Kw≈1–2, about 12% of the extracellularly applied cyclic
nucleotide concentration is detected inside platelets and
CHO cells (8-Br-cGMP and Rp-cAMPS). At higher lip-
ophilicity (log Kw≈2.5), passive diffusion increases, and
intracellular cyclic nucleotide concentration raises up to 20%
(8-pCPT -cGMP) and even 30% (8-Br-PET -cGMP; log Kw=
2.83) of the external concentration. The relative lipophilicities
oftheanalogscalculatedfromtheexperimentallyobtainedlog
Kw data (Table 4) correlate linearly with the amount
permeated (r
2=0.99; shown for cGMP scale in Fig. 1a).
Extrapolation of this linear approximation predicts 45%
diffusion for Rp-8-Br-PET-cGMPS, a compound with log
Kw≈3 (relative lipophilicity, 200). However, this analog does
not bind to the cGMP antibody in the EIA and therefore
could not be tested to substantiate/confirm this assumption.
With this linear model of relative lipophilicities, the actual
intracellular concentration of a cyclic nucleotide can be
predicted from its known lipophilicity.
Comparable data were obtained in an earlier study
analyzing cAMP analog permeation in rat C6 glioma cells.
Incubation with 8-Br-cAMP (log Kw=1.35) revealed an
intracellular concentration of about 8%, while the more
lipophilic 8-pCPT-cAMP (log Kw=2.65) reached 22% of
the applied extracellular concentration (Bartsch et al. 2003).
The equilibrium of inside/outside concentration of cNMPs
fairlyresistanttointracellularmetabolismlike8-Br-cGMP(16)
or 8-pCPT -cGMP (22) is achieved after 10–20 min (Fig. 1b).
Longer incubation times (up to 60 min) did not considerably
increase the intracellular concentration of the analog (not
shown). Hence, incubation times of 20 min are sufficient to
ensure adequate loading; however, we never observed an
intracellular concentration close to the external concentration
(assuming a bidirectional analog passage). The molecular
basis for this apparent imbalance might be explained by an
active transport of cyclic nucleotide analogs from the cytosol
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Fig. 1 a Effect of cyclic nucleotide lipophilicity on cell membrane
permeability in platelets. Error bars represent SD of three independent
experiments. Shown are the data for 8-Br-cGMP (analog 15), 8-pCPT-
cGMP (analog 16) and 8-Br-PET-cGMP (analog 22). b Time-
dependent influx of cyclic nucleotides. Platelets were incubated with
3nM 8-pCPT-cGMP (analog 16) or 8-Br-PET-cGMP (analog 22) for
the time points indicated, and the intracellular analog concentration
was measured. Error bars represent SD of two independent experi-
ments in duplicate
a
0      1     2     5    10   20   min 
0.25 µM 8-Br-PET-cGMP 
50 µM 8-pCPT-cGMP
200 µM 8-Br-cGMP
2 mM 2`-dcGMP
b
0      1     2     5    10   20   min 
100 µM 5,6-DCl-cBIMPS
500 µM 8-Br-cAMP
2 mM 2`-dcAMP
Fig. 2 Cyclic nucleotide stimulated V ASP phosphorylation in intact
human platelets. Cells were incubated with different concentrations of
cyclic nucleotide analogs for the time points indicated. Proteins were
separated by SDS-PAGE and subjected to western blot analysis for
V ASP phosphorylation with PKG-specific pV ASP antibody 16C2 (a)
or PKA-specific pV ASP antibody 5C6 (b)
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process of cellular cAMP and cGMP secretion by an apical
plasma membrane transporter or by members of the
multidrug resistance protein family (MRP4 and MRP5)
against concentration gradients was reported in various cells
like hepatocytes, vascular smooth muscle cells, epithelial
cells, neuronal cells and platelets (Sager and Ravna 2009).
This unidirectional A TP-activated process is analog- and
concentration-dependent, and thus might explain for the
observed intracellular cNMP accumulation during the first
5 min (Fig. 1b) before active extrusion commences.
Overall, the intracellular levels of externally applied
cyclic nucleotides depend on more than simple membrane
permeability; however, independent of the occurring mem-
brane processes, our data depict a correlation between
cNMP lipophilicity and intracellular accumulation that can
be used for the design of in vivo experiments.
Western blot analysis
Western blot analysis of vasodilator-stimulated phospho-
protein (V ASP), which is highly expressed in platelets, was
selected to prove the correlation between lipophilicity and
cell membrane permeability of cyclic nucleotide analogs.
V ASP is one of the most prominent substrates of cAMP-
and cGMP-dependent protein kinase (PKA II and PKG Iβ,
respectively; Butt et al. 1994), which in turn are major
targets of cAMP and GMP in platelets.
8-pCPT-cGMP (Ka=0.9 μM) and 8-Br-cGMP (Ka=
1.0 μM) show similar PKG Iβ activation constants but
exhibit different lipophilicities (Table 3). After 20 min,
maximal V ASP phosphorylation is achieved with 50 μM8 -
pCPT-cGMP (log Kw=2.52; permeability≈20%), while for
8-Br-cGMP (log Kw=1.17, permeability≈10%), 200 μMi s
required to achieve the same effect (Fig. 2a). For 8-Br-PET-
cGMP (permeability≈30%; Ka=0.009 μM), even 0.25 μM
are sufficient to activate PKG in human platelets (Fig. 2a).
In contrast, no V ASP phosphorylation is observed with 2′-
dcGMP (Ka=21 μM, log Kw=0.66) at concentrations up to
2 mM due to the lack of cell membrane permeability of this
compound (Fig. 1b).
For PKA activation experiments, the compounds Sp-5,6-
DCl-cBIMPS and 8-Br-cAMP were selected. Both analogs
exhibit similar activation constants but different lipophilic-
ities (Table 3). To detect comparable V ASP phosphorylation,
only 100 μM of the more lipophilic compound Sp-5,6-DCl-
cBIMPS (Ka=0.12 μM, log Kw=2.99) is needed, while for
8-Br-cAMP (Ka=0.09 μM, log Kw=1.35), 500 μM has to
be applied (Fig. 2b). Similar to 2′-dcGMP , no V ASP
phosphorylation is seen with the impermeable compound
2′-dcAMP (Fig. 2b).
In summary, with the exception of Rp-cAMPS, 8-Br-
cGMP and 8-pCPT-cGMP , all analogs used in this study do
not interfere with the tested cAMP and cGMP enzyme
immunoassays from ENZO. For higher specificity, the
Cayman cGMP-EIA is suggested. Overall, when assessing
cAMP and cGMP levels in the presence of cNMP analogs,
cross-reactivity tests with the used immunoassays used are
strongly recommended.
Data acquired with immunoassays for cyclic nucleotides
in the presence of cyclic nucleotide derivatives should be
taken with great care, and conclusions based on these data
carefully reappraised in the light of this study.
The amount of intracellularly accumulated analog was
found to be 10–30% of the extracellular applied concentra-
tion, predominantly depending on the lipophilicity index of
the respective compound. Experiments with cyclic nucleo-
tide analogs in living cells should be designed, taking these
observations into account. Our data provide a useful basis
for scientists in the field of cyclic nucleotide regulation in
living cells.
Open Access This article is distributed under the terms of the Creative
Commons Attribution Noncommercial License which permits any
noncommercial use, distribution, and reproduction in any medium,
provided the original author(s) and source are credited.
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